CreaTek Solutions Reports Phase 2b Study of Cardia-7 for Heart Failure Did Not Meet Primary Endpoint

SAN FRANCISCO, CA â€“ CreaTek Solutions announced today that its Phase 2b trial for Cardia-7, a novel therapy for chronic heart failure, did not achieve its primary endpoint of a significant reduction in cardiovascular events. The trial, which included 475 participants, was well-tolerated but ultimately the outcome was marked as failed. The company will analyze the full data set to determine the future of the program.
